Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

3 Pharma Stocks Ready to Shine This Week

The pharmaceutical industry is expected to thrive, driven by the increasing need for chronic disease management and the requirements of an aging demographic. Given the industry’s solid prospects, quality pharma stocks Organon (OGN), GoodRx Holdings (GDRX), and Collegium Pharmaceutical (COLL) could be solid buys this week. Read on….

StockNews.com

Earnings Watch: Is Walgreens Boots Alliance (WBA) a Solid Buy Before Earnings?

Retail drugstore chain Walgreens Boots Alliance (WBA) achieved adjusted EPS growth on solid sales increase in the third quarter of fiscal 2023. However, the company lowered its full-year earnings guidance to reflect challenging consumer and macro conditions and lower COVID-19 demand. So, let’s determine if WBA is a buy before…

StockNews.com

Georgia will be first state with medical marijuana in pharmacies

Georgia soon will become the first state in the nation to offer medical marijuana products at independent pharmacies

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Pharma Stocks With Potential to Outperform Pfizer Inc. (PFE) in October

Pfizer (PFE) is grappling with financial difficulties and declining performance. Yet, with growing pharmaceutical demand and industry advancements, robust pharma stocks Zoetis (ZTS), Horizon Therapeutics (HZNP), and Novartis (NVS) appear as more promising buys this month. Read on.

StockNews.com

Which Pharma Stock Has More Potential Gains This Month: Pfizer (PFE) or Eli Lilly & Co. (LLY)?

The pharmaceutical industry is poised for sustained long-term growth due to increased investments in drug development and rapid technological advancements. While leading pharma stocks Pfizer (PFE) and Eli Lilly (LLY) stand to benefit, let us analyze which of these giants is poised for more gains this month. Keep reading.

StockNews.com

IBD 50 Stocks To Watch: Drug Leader McKesson Eyes Buy Point Amid Market Sell-Off

Among the best stocks to buy and watch, drug giant McKesson is near a new buy point after Tuesday's stock market sell-off.

Investors Business Daily

Teva Leans Into Sanofi's 'Pipeline-In-A-Product' Expertise In $1.5 Billion Deal

Teva stock tumbled Wednesday after the company announced it would partner with Sanofi to develop an inflammatory bowel disease treatment.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Top 3 Biotech Stocks Leading the Way This October

The biotech industry is well-positioned for strong growth thanks to increasing demand for high-quality treatments for chronic diseases. Given this backdrop, quality biotech stocks Jazz Pharmaceuticals (JAZZ), Amgen (AMGN), and Gilead Sciences (GILD) could be solid buys for October. Read on….

StockNews.com

Letters to The Editor — October 3, 2023

Readers’ mail to The Hindu’s Letters to The Editor

The Hindu

Viatris Stock Bounds Higher As Divestitures Reach Nearly $7 Billion

Viatris stock popped Monday after the company announced it would divest most of its over-the-counter and women's health businesses.

Investors Business Daily

Johnson & Johnson not to enforce patents on TB drug

“The announcement will finally pave the way for unfettered access to affordable generic versions of bedaquiline for all people”

The Hindu

These 5 Stocks Are Setting Up This Buying Opportunity After Strong Runs

After a run, stocks can offer a new buying opportunity with a pullback to the 50-day line. Novo Nordisk and 4 S&P 500 stocks have done that.

Investors Business Daily

Have a complaint about CVS? So do pharmacists: Many just walked out

After a large walkout forced at least a dozen stores to shut down in the Kansas City area, CVS promises change. But critics say the crisis in staffing and unfair pay extends beyond that market.

WEKU

Vivek Ramaswamy is furiously defending his business ties in China. What are they?

‘Vivek’s first business had a subsidiary in China’ which was closed ‘as the risks of doing business in China became apparent,’ Ramaswamy spokesperson says

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Biotech Stocks to Buy Instead of Palatin Technologies (PTN)

While Palatin Technologies (PTN) has faced challenges with declining share price, negative analyst projections, and limited profitability, it's worth noting the consistent growth in the broader biotech industry. Thus, investors could find more stable returns in robust biotech stocks Protalix BioTherapeutics (PLX), Exelixis (EXEL), and Jazz Pharmaceuticals (JAZZ) instead. Read…

StockNews.com

3 A-Rated Pharma Buys for October

The growing adoption of innovative drugs and the heightened demand for personalized medicines are expected to boost the pharma industry. Therefore, it might be wise to buy fundamentally strong pharma stocks Neurocrine Biosciences (NBIX), Novo Nordisk (NVO), and AstraZeneca PLC (AZN), which are rated an A (Strong Buy) in our…

Newslaundry

‘My posts are backed up with solid evidence, research’: Liver Doc on Himalaya Wellness suit

“Based on strong scientific evidence, or because of lack of it, I have been critical of several of Himalaya Wellness’ products,” said doctor-influencer Cyriac Abby Philips aka The Liver Doc, whose X account was suspended today for posting “defamatory remarks” against the ayurvedic pharma company.

The Guardian - UK

People with HIV offered hope of self-injected drug at home

GSK-controlled company works on developing patient-administered treatment by end of the decade

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment

Crispr is facing its make-or-break moment and, experts say, a pivotal decision in December could spark more than just beleaguered CRSP stock.

Chicago Sun-Times

Common children’s antibiotic amoxicillin still in short supply for the second year

While pharmacies say they can still fill most prescriptions for amoxicillin, the most-prescribed drug in the country, the shortage could worsen when the viral season hits this winter, experts say.

Investors Business Daily

Biohaven, Yet Another Rival To Argenx In Autoimmune Drugs, Just Rocketed 33%

Biohaven could rival Argenx and Immunovant after unveiling results Wednesday for an autoimmune diseases drug. BHVN stock rocketed.

Investors Business Daily

Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering

Immunovant stock reversed lower Wednesday after the company announced a $300 million offering. IMVT stock almost doubled Tuesday.

The National (Scotland)

New York drug consumption rooms to influence Glasgow pilot, First Minister says

GLASGOW’S pioneering drug consumption room will be shaped by research carried out in New York City, the First Minister has said.

Newcastle Herald

'Easier access': Oral contraceptives from pharmacies

'Recognition of the capabilities that pharmacies have.'

Investors Business Daily

The $660 Million Opportunity That's Driving IBD Stock Of The Day Neurocrine Biosciences Higher

Neurocrine is Tuesday's IBD Stock Of The Day. After it unveiled promising results for a genetic disease drug, NBIX stock is on the rise.

1 … 28 29 30 31

People

Mangeet Kaur BounsMangeet

595 stories

Sristi Suman JayaswalThe

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Scottish Government

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.